EC conditionally approves Pfizer’s haemophilia B gene therapy
The approval is based on data from the Phase III BENEGENE-2 clinical trial of DURVEQTIX.
Approvals
InnoCare receives clearance for leukaemia/lymphoma trial in China
FDA grants IND clearance for OKYO Pharma’s NCP treatment trial
Neurotech to begin Phase I/II trial of NTI164 for cerebral palsy
Kyverna Therapeutics given FDA approval for KYV-101 trial
Antengene gets FDA approval for Phase I trial of cancer drug
Phio Pharmaceuticals receives FDA IND clearance for PH-762 trial
Stoke Therapeutics receives approval to begin Phase l/ll trial of ADOA therapy
